Efficacy and Safety of Intravitreal Aflibercept for Neovascu
Treating neovascular age-related macular degeneration with intravitreal aflibercept treat-and-extend (T&E) can reduce treatment burden. ARIES assessed whether intravitreal aflibercept early-start T&E was noninferior to late-start T&E.

A randomized study included treatment-naive patients aged more than 50 years with the best-corrected visual acuity 73–25 Early Treatment Diabetic Retinopathy Study letters and active choroidal neovascularization secondary to AMD. Patients received 2 mg intravitreal aflibercept at Week (W) 0, 4, 8, and 16.

--271 patients were randomized. The mean (SD) best-corrected visual acuity at baseline was 60.2 and 61.3 letters.

--The mean (SD) best-corrected visual acuity change (W16–104) was 2.1 versus 0.4 letters; +4.3 versus +7.9 letters (W0–104).

--The mean (SD) number of injections was 12.0 versus 13.0.

--From baseline to W104, 93.4% and 96.2% maintained best-corrected visual acuity; the mean (SD) central retinal thickness change was 161.6 micro m and 158.6 micro m.

--The last injection interval (W104) was more than 12W for 47.2% and 51.9% of patients.

Conclusively, following initial dosage, outcomes were similar amongst individuals with neovascular age-related macular degeneration who received an intravitreal aflibercept early-T&E or late-T&E regimen, with one injection difference over two years.

Source: https://journals.lww.com/retinajournal/Fulltext/2021/09000/EFFICACY_AND_SAFETY_OF_INTRAVITREAL_AFLIBERCEPT.15.aspx